SMC
RVMD icon

Smith, Moore & Co’s Revolution Medicines RVMD Stock Holding History

Smith, Moore & Co’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$584K Hold
6,000
– – 0.04% 301
2025
Q4 		$478K Hold
6,000
– – 0.04% 326
2025
Q3 		$280K Buy
+6,000
New +$235K 0.02% 423

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Smith, Moore & Co's RVMD Position: Q1 2026 in Review

Smith, Moore & Co held its Revolution Medicines (RVMD) position steady in Q1 2026 at 6,000 shares worth $584K. The position accounts for 0.04% of the portfolio, ranked #301.

Smith, Moore & Co first reported a position in RVMD in Q3 2025 and has held it in 3 quarters since. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Smith, Moore & Co held 6,000 shares of Revolution Medicines worth $584K as of Q1 2026.
  • Smith, Moore & Co left its Revolution Medicines share count unchanged in Q1 2026.
  • Revolution Medicines made up 0.04% of Smith, Moore & Co's portfolio in Q1 2026, its #301 holding.
  • Smith, Moore & Co first reported a position in Revolution Medicines in Q3 2025 and has held it in 3 quarters since.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Smith, Moore & Co's 13F filing for Q1 2026, filed 5 May 2026.